Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Cash from Financing Activities data on file, last reported at -$5.4 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 116.62% year-over-year to -$5.4 million in Q1 2026; TTM through Mar 2026 was $180.1 million, a 17.97% decrease from a year earlier, with the FY2025 full-year figure at $218.0 million, up 13.97% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$5.4 million, down from -$2.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for RYTM reached as high as $189.3 million in Q3 2025 and fell as low as -$5.4 million in Q1 2026.
• Historically, Cash from Financing Activities has averaged $40.7 million across 5 years, with a median of $4.2 million in 2024.
• Across the five-year window, Cash from Financing Activities soared 38293.22% in 2022 and plunged 133.33% in 2023, its largest moves.
• Year by year, Cash from Financing Activities stood at $17.4 million in 2022, then sank by 86.05% to $2.4 million in 2023, then surged by 1481.84% to $38.3 million in 2024, then slumped by 107.69% to -$2.9 million in 2025, then plunged by 83.18% to -$5.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$5.4 million in Q1 2026, -$2.9 million in Q4 2025, and $189.3 million in Q3 2025.